Immatics Appoints Harpreet Singh as Chief Executive Officer

(PresseBox) ( Tuebingen, Germany / Houston, Texas, )
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer (CEO).

Harpreet Singh has most recently been President and CEO of Immatics US and Chief Scientific Officer (CSO) of the Company, having co-founded Immatics. He has been instrumental in growing the Company from a start-up to a leading player in the field of immuno-oncology.

Peter Chambré, Chairman of Immatics, says: “The Board is delighted to appoint Harpreet as CEO to lead Immatics in the next phase of its development, as the Company progresses its pipeline of immunotherapy candidates. Harpreet is an exceptional organizational leader and scientist and over the past three years has led the building of the Immatics US organization and creation of Immatics’ clinical pipeline and capabilities in adoptive cellular therapy, as well as guiding the Company’s overall scientific development since its early days. We are very excited about the prospects and opportunities for Immatics, with Harpreet as CEO.”

Harpreet Singh comments: “I am thrilled to be chosen as CEO of Immatics. We hold the key to unlock the power of cancer immunotherapies in solid cancers. Built on world-leading target and TCR discovery platforms we are developing powerful pipelines of novel adoptive cellular as well as bispecific therapy products - on our own, as well as with world-class partners. The opportunity to lead this exceptional company and its outstanding people that are passionately dedicated to delivering the power of T cells to cancer patients, is a true privilege.”

About Harpreet Singh, Ph.D.

Harpreet co-founded Immatics in 2000 to translate pioneering scientific discoveries in immunology into highly innovative immunotherapies to impact the lives of cancer patients.

Since the foundation, he has served as Managing Director and Chief Scientific Officer, helping to grow the Company from a start-up to a leading biotech player in the field of immuno-oncology. Harpreet has played a leadership role in raising more than US$200m of venture capital funding over several financing rounds. In 2015, Harpreet became President & CEO of Immatics US, overseeing all operations of Immatics in Houston, Texas to develop next-generation Adoptive Cell Therapies (ACT). He led the team that achieved a $20m CPRIT grant by the State of Texas. Harpreet was awarded "Private Company CEO of the Year" at the Lifestars Awards 2018 (in association with Jefferies), in recognition of his achievements. In 2019, Harpreet became CEO of Immatics Biotechnologies.

Harpreet is the inventor on numerous granted patents and patent applications and co-author of numerous scientific papers published by peer-reviewed journals including Nature, Nature Medicine, Nature Biotechnology, Lancet Oncology. A scholar of Prof. Hans-Georg Rammensee, Harpreet completed his academic studies by gaining a Ph.D. in immunology at the University of Tuebingen, Germany.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.